Join to access to all OVN content. Join for Free

Results for 'organic traffic growth'

...
Partner Avatar Tom Caravela
12 Interview Techniques to Help Land Your Next Job

May 12th • 1 min read

...
Partner Avatar Tom Caravela
MSL Retention – What Matters Most

Mar 15th • 2 mins read

...
Partner Avatar Tom Caravela
INTENTION: The Key to Achieving Your Goals

Jan 21st • 1 min read

...
Partner Avatar Tom Caravela
MSL Evolution: New Trends and Titles That May Emerge

Apr 5th • 1 min read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 21st • 10 mins read

...
OVN Avatar Ali Raza Khaki
Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Dec 1st • 4 mins read

...
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Leveraging existing data to contextualize phase II clinical trial findings in oncology

Sep 21st • 3 mins read

...
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Jun 26th • 18 mins read

...
OVN Avatar Tanja Cufer, Tudor E. Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopovic, Jacek Jassem, Dragana Jovanovic, Zhasmina Mihaylova, Gyula Ostoros, Christiane Thallinger, Milada Zemanova, Christoph Zielinski
Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

Nov 24th • 10 mins read

...
OVN Avatar Jingjing Yu, Isabelle Ragueneau-Majlessi
In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018

Jan 25th • 12 mins read

...
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD
Evaluating External Validity of Oncology Biosimilar Safety Studies

Apr 6th • 2 mins read

...
OVN Avatar Patrick C. DeMartino, MD, Miloš D. Miljković, MD, MS, Vinay Prasad, MD
Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018

Aug 31st • 7 mins read

...
OVN Avatar Steven Sorscher
Clinical Trials in Oncology and Defining Benefit

Jan 22nd • 1 min read